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In humans, the glucocorticoid corticosterone circulates
in blood at 10–20-fold lower levels than cortisol, but is found in
higher relative amounts in postmortem brain samples. Access of
cortisol and corticosterone to the central nervous system may not
be equal. Additionally, the relative affinities for the glucocorticoid and
mineralocorticoid receptors differ, such that corticosterone may play




We measured cortisol and corticosterone levels in paired
plasma and cerebrospinal fluid (CSF) samples. To test the relative




 corticosterone on hypothalamic–pituitary–
adrenal (HPA) feedback, subjects underwent a three-phase, single-
blind, randomized study assessing the postmetyrapone ACTH
response over 3 h to an intravenous bolus of vehicle, cortisol or




Outpatients undergoing diagnostic lumbar puncture
who were subsequently deemed to be free of disease. Feedback was




Plasma and CSF corticosterone to cortisol ratio


















 0·001). Cortisol and









there was no difference between corticosterone and cortisol. The





Corticosterone contributes almost 40% of total
active glucocorticoids (cortisol and corticosterone) in the CSF.
Significant effects on HPA axis suppression were only seen with
supraphysiological levels of corticosterone, suggesting that cortico-
sterone is not important in this model of nonstress-induced ACTH
hypersecretion, in which the effect of cortisol predominates.
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Corticosterone is the predominant circulating glucocorticoid in
rodents, but in humans it circulates at 10–20-fold lower concentra-





humans, corticosterone is considered an intermediary in the forma-
tion of aldosterone; no specific role has been attributed to it. However,
the multidrug resistance 1a (mdr1) P-glycoprotein membrane pump,
which is highly expressed on the luminal surface of endothelial




 reduces access of the synthetic













 using cells transfected with the





 By contrast, corticosterone is not a substrate for mdr1a and









alongside postmortem observations that the corticosterone : cortisol




 have led to the sug-
gestion that corticosterone might play a more prominent role than





Glucocorticoid levels are tightly regulated by the activity of the
hypothalamic–pituitary–adrenal (HPA) axis, itself subject to nega-
tive feedback control by glucocorticoids. Such central feedback is
mediated by both mineralocorticoid (MR) and glucocorticoid recep-
tors (GR) at several specific brain sites and, outside the blood–brain




 GR are lower affinity receptors that are dis-
tributed throughout the brain, but are particularly highly expressed
in hypothalamic paraventricular nucleus neurones and corticotroph
cells of the pituitary, while the higher affinity MR are mainly located





ative roles of these two receptor subtypes in mediating corticosteroid
feedback regulation of the HPA axis in different situations have not
been fully resolved. GR are thought to play a major role in stress-
responsive feedback because even at high levels of glucocorticoids




MR have a much higher affinity for glucocorticoids so that they are
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 and have accord-
ingly been proposed to play a major role during the nadir of gluco-
corticoid production, in the evenings in humans, in maintaining




















 using the MR antagonist spironolac-
tone, showed that MR blockade affected HPA axis secretion at both
the peak and the nadir of the circadian rhythm, even at times when
GR was previously believed to be playing the major role in mediating
glucocorticoid negative feedback.
The potential ‘privileged’ uptake of corticosterone in the brain
might be expected to promote its receptor occupancy relative to cor-
tisol. There is evidence that corticosterone has a higher affinity for




 and thus it is possible that glucocorticoid-
mediated effects on hippocampal functioning might reflect corticos-
terone acting through MR rather than cortisol.
We first aimed to measure cortisol and corticosterone in paired
samples of plasma and cerebrospinal fluid (CSF) from living subjects





. Thereafter we compared the effect of cortisol
and corticosterone on ACTH suppression in a model of nonstress-
induced ACTH hypersecretion after metyrapone administration.
Metyrapone reduces cortisol and corticosterone production in the





hydroxylase (cyp11b1). Metyrapone also crosses the blood–brain
barrier and blocks local generation of cortisol in the central nervous




-hydroxylase in the brain but




-hydroxysteroid dehydrogenase type 1, which
regenerates both cortisol and corticosterone locally within neurones







All studies were approved by the local research ethics committee and






We could not ethically justify doing a lumbar puncture on
normal volunteers. CSF and venous blood were thus obtained within
5 min of each other from patients undergoing routine lumbar punc-
ture as part of a work-up for possible neurological disease. All lumbar
punctures were performed in the afternoon between 1430 and
1630 h. Of 23 sequential lumbar punctures performed, 11 were
included for analysis in this study. Patients (mean age 39·2, range
23–70 years) were considered suitable for inclusion if no firm diag-
nosis of neurological disease affecting the central nervous system or
blood–brain barrier was reached within 6 months following the
lumbar puncture and if the CSF was normal with normal microscopy
(with no white or red blood cells seen), cytology and biochemistry
with normal CSF protein, albumin, immunoglobulin G (IgG) index
and CSF : serum albumin ratio. No patients were on treatment with
glucocorticoids for the preceding 6 months. Clinical indications for
lumbar puncture were chronic headache (five patients), possible
multiple sclerosis (four patients), polyneuropathy (one) and possible




Ten healthy men of normal weight with no previous glu-
cocorticoid exposure [mean age 32·5, range 23–45 years; mean body
mass index (BMI) 22·9, range 20·7–25·2] underwent a three-phase,
single-blind, randomized study assessing the postmetyrapone
ACTH response over 3 h to an intravenous bolus of vehicle, cortisol
(F) or corticosterone (B) (0·15 mg/kg). Six individuals underwent
a further two phases using lower doses of F and B (0·04 mg/kg). Sub-
jects were volunteers from the community in excellent physical and
mental health as determined by an interview, a physical examination,





For each phase, at least a week apart, subjects took two separate
oral doses of 750 mg metyrapone (Novartis, London, UK) at 0000 h
and at 0600 h on the day of the study and attended the clinical
research facility after an overnight fast. An intravenous catheter was
inserted into an antecubital vein and subjects remained sedentary
in bed for the period of the study. Basal plasma samples were col-
lected between 0830 and 0900 h. Then, in random order, subjects
were given an intravenous bolus (50 ml over 2 min) of (i) vehicle
(0·9% saline); (ii) 0·04 mg/kg cortisol (hydrocortisone sodium suc-
cinate in 50 ml saline; Solu-Cortef, Pharmacia, Surrey, UK); (iii)
0·15 mg/kg cortisol; (iv) 0·04 mg/kg corticosterone (2% ethanolic
solution; Calbiochem, EMD Biosciences Inc., San Diego, CA, USA);
or (v) 0·15 mg/kg corticosterone. Blood samples were collected on













In study 1, CSF cortisol was measured with a sensitive salivary cor-
tisol enzyme-linked immunosorbent assay (ELISA) kit (Salimetrics
LLC, State College, PA, USA), plasma cortisol with an in-house radio-
immunoassay and CSF and plasma corticosterone with an ELISA
kit (Immunodiagnostic Systems Ltd, Boldon, UK). The cross-
reactivity for corticosterone was 0·2% for the plasma cortisol assay and
0·1% for the CSF cortisol kit. The cross-reactivity of the corticoster-
one kit for cortisol, deoxycorticosterone, cortisone, 11-deoxycortisol
and 17-OH progesterone was < 0·02%. In study 2, ACTH was meas-
ured by an ELISA kit (Biomerica, Newport Beach, CA, USA), plasma
cortisol by ELISA, which does not cross-react with 11-deoxycortisol
(DRG International Inc., East Mountainside, MG, USA), and corti-
costerone by ELISA as in study 1. The cross-reactivity of the plasma
cortisol assay for corticosterone was 45% (but because plasma cor-
ticosterone is suppressed to < 20 nmol/l after metyrapone, this was
considered negligible) and for deoxycorticosterone, 11-deoxycortisol,
cortisone and 17-OH progesterone was < 2%. Importantly, the
cross-reactivity of the plasma cortisol assay for hydrocortisone
sodium succinate (Solu-cortef) was < 2%. Inter- and intra-assay




For study 1, pairwise comparisons between groups were carried out




-test. For study 2, overall effects, summarized
by the area under the curve (AUC) were assessed by two-way analysis
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Dunnett’s test or Fisher’s LSD test for comparison of equal dose infu-













Plasma to CSF ratios of corticosterone and cortisol
 




 68·4 nmol/ l (normal range
83–414 nmol/ l), suggesting subjects were stressed at the time of




 9·2 nmol/ l. The




 0·007, in keep-













 0·9 nmol/ l. The




 0·050; this is







ACTH suppression to cortisol and corticosterone
 
As expected, baseline plasma ACTH levels in the morning were ele-
vated after metyrapone at 31·8 pmol/ l (normal range 2–11·4 pmol/ l).




 9·8 nmol/ l
(normal range 138–634·8 nmol/ l), confirming inhibition of gluco-
corticoid synthesis by metyrapone. After vehicle injection, plasma
levels of ACTH, cortisol and corticosterone remained steady for the
180 min of the study (data not shown).
ACTH levels were significantly suppressed (Fig. 2) by both
0·15 mg/kg cortisol and 0·15 mg/kg corticosterone when compared

































 = 0·014). There were, how-
ever, no differences in overall response between cortisol and corti-




 0·41). Although the
maximum percentage change in ACTH from baseline was greater








 = 0·002), this difference appeared





 = 0·007; Fig. 2), which coincided with higher plasma levels
of cortisol than corticosterone levels. ACTH levels after 0·04 mg/kg
corticosterone or cortisol were not significantly different from vehicle
or each other.
Plasma corticosterone and cortisol peaked within 5 min of the
bolus dose, and then steadily declined over the next three study hours
(Fig. 2). The concentrations of corticosterone achieved a signific-
antly higher peak and declined faster to lower levels than those of





















 17·5 min). Plasma levels of corticosterone and
cortisol were thus not directly comparable across the study, most
likely because of the delay in conversion of the inactive hydrocorti-
sone sodium succinate (injected as Solu-cortef) to hydrocortisone




 and/or because of differing pool sizes of the
Fig. 1 The ratio of corticosterone over cortisol in human plasma and 
cerebrospinal fluid (CSF). Data are presented as mean ± SEM. *P < 0·001.
Fig. 2 Plasma ACTH levels (a,b) and 
corresponding cortisol (F) and corticosterone 
(B) levels (c,d) over time following a bolus dose 
of 0·15 mg/kg (a,c) or 0·04 mg/kg (b,d) cortisol 
(given as hydrocortisone sodium succinate) or 
corticosterone at time 0. Data are mean ± SEM and 
are presented as absolute values; analysis was by 
summary measures calculated from the curves.
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different steroids and/or because of different elimination half-lives




We have shown that the ratio of corticosterone to cortisol is signi-
ficantly greater in human CSF than in plasma, with corticosterone
contributing almost 40% of total active glucocorticoids (cortisol and
corticosterone) in the CSF, whereas in plasma corticosterone is only














extracted glucocorticoids from human postmortem brain samples.
This present analysis was performed at a time of stress due to lumbar
puncture, which was reflected in the high plasma cortisol and cor-
ticosterone concentrations measured. It may be that the data may
not reflect the situation at times of low basal circulating glucocorti-




 reason to infer this. The relatively
higher levels of corticosterone in CSF could be due to differential
responses of cortisol and corticosterone to stress/ACTH. However,
there is no evidence to suggest that cortisol and corticosterone
respond differently to stress. Indeed, cortisol and corticosterone levels
change in parallel both with the normal diurnal rhythm of gluco-




The plasma ratio for corticosterone to cortisol here is consistent with




 It is pos-
sible that corticosterone is less bound to corticosteroid-binding glob-
ulin (CBG) than cortisol and thus more corticosterone is available
for transport. However, the affinity of cortisol and corticosterone for




 Finally, there may be differences in
the rate of transport of the steroids into and/or clearance from the
CSF. The relative rate of transport of cortisol and corticosterone into





 so this seems unlikely to account for proportionately
higher corticosterone in CSF. It seems most plausible that propor-




 reflects a difference in
rate of clearance of cortisol and corticosterone from the CSF. The
most likely candidate mechanism is the blood–CSF barrier mdr1a
P-glycoprotein membrane pump, as differences in bulk clearance
from CSF, a passive process, seem intrinsically improbable. Both the
blood–brain barrier and the blood–CSF barrier express MDR1; the
blood–CSF difference measured is therefore also likely to be reflected
by differential access of corticosterone across the blood–brain barrier.
These data provide further support for the argument that the two
steroids may not have equal access through the blood–brain barrier
and suggest that the contribution played by corticosterone in
glucocorticoid signalling in the brain is likely to be significant.
Further mechanistic studies to investigate why this difference is
present are clearly required. However, cortisol levels still exceed those
of corticosterone in CSF, suggesting that it is the predominant signal
even in the brain. Whether or not the greater affinity of corticosterone
for MR tips the balance significantly in favour of this steroid under
some circumstance remains uncertain.
We also report the first study on the action of corticosterone in
human HPA feedback. We hypothesized that corticosterone would
be more potent than cortisol in feedback. The results suggest that
corticosterone does not play a predominant role in HPA feedback
in this model of modest ACTH hypersecretion. Plasma levels of cor-
tisol approached high physiological levels in the high-dose study and
modest physiological levels in the low-dose study. A typical feedback
response to a bolus dose of glucocorticoid was seen with ACTH levels
starting to decline about 45 min after the bolus, with a maximal
response after 2–3 h. Because of unexpected differences in plasma
hormone concentrations after bolus injection, the study should be
interpreted with caution. Peak plasma corticosterone levels at both
doses were higher than cortisol levels and much higher than corti-
costerone levels expected even in response to severe stress. Despite
this, the feedback by corticosterone was not more potent than cor-
tisol. Indeed, there was no measurable ACTH suppression following
the lower dose of corticosterone despite plasma levels high above
physiological. Thus there is no evidence in favour of greater potency
of corticosterone under the conditions tested.
This study examined acute effects of bolus doses designed to




 brain feedback in humans in response to endogenous glucocor-
ticoids in this setting is not known, although a similar approach





 with the available evidence suggesting
that feedback to a bolus dose occurs at pituitary and central levels.
This raises the question of whether cortisol and corticosterone are
predominantly acting through the same or different glucocorticoid
receptors centrally (GR or MR). Corticosterone has a lower affinity
for GR than cortisol, and is less effective as an anti-inflammatory










 The lack of potency of corticosterone in HPA feed-
back suppression does not support the increase in levels of an MR
preferential ligand in HPA axis suppression. This is perhaps unsur-
prising in the light of data from rodents suggesting that hippocampal








so large rises in steroid levels are anticipated to have little additional
effect through this receptor. By contrast, GR are largely unoccupied
under basal conditions, so rising levels of a preferential GR agonist
such as cortisol may have greater effects in feedback suppression.





This study does not support the contention that corticosterone is
the predominant glucocorticoid affecting the brain in humans, at
least in the situation of stress-type feedback. However, the possibility
remains that corticosterone is important in central brain function
because of the high concentrations found in CSF and brain and the
reported relative affinity for MR over GR compared with cortisol.
The proportional occupancy of MR and GR is also likely to differ
across the range of circulating corticosteroid concentrations, such
that we have not excluded the possibility that corticosterone is
important in feedback in situations when signalling through MR
may be dominant. Corticosterone may also play a role in more
chronic effects upon the HPA axis or other CNS functions influenced
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